HBV: Clinical Trials

4 completed, 1 terminated, 1 unknown. 6 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	6	Completed 4, Terminated 1, Unknown 1
Phase 2	1	Completed 1

Follow HBV: new trials by email Literature Review of HBV trials Research Report on HBV

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA Tenofovir, Entecavir - B-cell Lymphoma, HBV	Phase 3	Unknown	Ruijin Hospital	120	2020-07-03	2020-09-04
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Engerix B, Fendrix - HIV, Communicable Diseases	Phase 2 / Phase 3	Completed	Sheffield Teaching Hospitals NHS Foundation Trust	13	2015-07-23	2022-09-29
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China) TAF, TDF, TAF Placebo - HBV, Chronic HBV Infection	Phase 3	Completed	Gilead Sciences	181	2015-06-19	2024-10-15
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China) TAF, TDF, TAF Placebo - HBV, Chronic HBV Infection	Phase 3	Completed	Gilead Sciences	155	2015-06-19	2024-10-02
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults E/C/F/TAF - HIV, HBV	Phase 3	Completed	Gilead Sciences	79	2014-02-25	2018-11-16
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures Eltrombopag, Placebo - Non-alcoholic Steatohepatitis, Chronic Liver Disease	Phase 3	Terminated	GlaxoSmithKline	292	2008-06-01	2018-10-12

Narrower conditions

Hepatitis (2)  ·  Hepatitis B (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Coinfection (1)  ·  Communicable Diseases (1)  ·  HIV Infections (1)  ·  Hepatitis C (1)  ·  Jacobs syndrome (1)  ·  Liver Diseases (1)  ·  Lymphoma, B-Cell (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Thrombocytopenia (1)

Broader conditions

Digestive System Diseases (4)  ·  Infections (3)  ·  Liver Diseases (3)  ·  Blood-Borne Infections (2)  ·  DNA Virus Infections (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Hepadnaviridae Infections (2)  ·  Hepatitis (2)  ·  Hepatitis, Viral, Human (2)  ·  Immune System Diseases (2)  ·  Virus Diseases (2)  ·  Blood Platelet Disorders (1)  ·  Communicable Diseases (1)  ·  Cytopenia (1)  ·  Disease Attributes (1)

Interventions

Tenofovir (3)  ·  tenofovir alafenamide (2)  ·  Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Engerix-B (1)  ·  Fendrix (1)  ·  eltrombopag (1)  ·  entecavir (1)

Sponsors

Gilead Sciences (3)  ·  GlaxoSmithKline (1)  ·  Ruijin Hospital (1)  ·  Sheffield Teaching Hospitals NHS Foundation Trust (1)

Countries

China (3)  ·  Canada (2)  ·  United States (2)  ·  Argentina (1)  ·  Belgium (1)  ·  France (1)  ·  India (1)  ·  Italy (1)  ·  Japan (1)  ·  Pakistan (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)

Results publications

PMID 37771546, PMID 22913681